Compounds for the treatment of mTOR pathway related diseases

A method for the treatment of one or more mTOR pathway related diseases, the method comprising administering a therapeutically effective amount of a compound of formula (I):

• or a pharmaceutically acceptable salt or solvate thereof, to a patient in need thereof, wherein the one or more mTOR pathway related diseases is selected from neurodegenerative diseases, age-related diseases, diseases related to transplant rejection, chronic inflammatory diseases, diseases related to glycogen storage, systemic lupus, diseases related to inflammation and immune activation, anaemia, leucopenia, thrombocytopenia, diseases related to stent coatings, renal insufficiency, obesity, diabetes/insulin resistance, diseases related to non-alcoholic fatty liver, polycystic kidney, and fibrosis and wherein
• i) R1 is alkyl, —CF3 or —CN, R4 is selected from H, alkyl, halogen, alkoxy, —CF3, —OCF3, —SO2—CF3, —SO—CF3 or —S—CF3 and R5 is independently selected from H, alkyl, halogen, —CF3 or —CN;
• or
• ii) R1 is selected from H or halogen, R4 is H, halogen, —S—CF3, —SOCF3 or —SO2CF3, and R5 is independently selected from H, halogen, or —CN;
• and
• R2 and R3 are each independently selected from H, alkyl, halogen, —CF3 or —CN;
• R6 is independently selected from H, alkyl, halogen, alkoxy, —CF3, —OCF3, —SO2CF3, —SOCF3 or —SCF3;
• X is heteroatom, N(alkyl) or NH;
• and
• n is 1 to 20.